Surgery Partners rejects a $28 bid, takes $25 a share from Bon Secours Mercy's HealthSpan
The surgery center chain chose a hospital system's raised offer over a higher cash bid, reported to be UnitedHealth's, because the board judged the bigger number less likely to close.

Surgery Partners, which runs more than 200 surgical locations in 30 states, said on Monday that it has amended its sale to HealthSpan Partners, an affiliate of Bon Secours Mercy Health, raising the cash price to $25.00 a share from $23.50 and the enterprise value to about $6.0 billion. The board took the raised offer after an unnamed third party proposed $28.00 a share in cash, according to the company's announcement1 filed with the Securities and Exchange Commission. Bloomberg reported the same day, citing a person familiar with the matter, that the bidder was UnitedHealth Group, which declined to comment.
Why it matters for what people pay
Ambulatory surgery centers are the setting insurers and employers steer patients toward because the same operation usually costs less there than in a hospital outpatient department. Who owns those centers shapes what that saving looks like. A hospital system buying one of the biggest chains folds the low-cost setting into a network that also negotiates hospital rates. An insurer buying it would have put the centers under the company that pays for the care.
Monday's filings also carry a live reading on surgery prices. Surgery Partners' third-quarter results2, released the same morning, show same-facility revenue up 6.0% on case volume up 0.2%. Revenue per case rose 5.8%. The company earned more by charging more per operation, not by doing many more of them.
The details
The competing proposal arrived on November 3 and was updated on November 8 to $28.00 a share, according to the company's announcement. A special committee of independent directors found it was not a "Superior Proposal" under the merger agreement. The committee said the rival deal would likely take materially longer to close, or might not close at all, carried greater regulatory risk and complexity, and lacked the contractual protections the committee had sought. The board approved the amended HealthSpan agreement on the committee's unanimous recommendation.
The amended deal adds a payment for delay. If stockholders approve the merger but it has not closed by March 1, 2027, holders other than Bain Capital receive cash at a 10% annual rate on the $25.00 price, paid monthly, up to $1.61 a share if the deal closes on the October 23, 2027 outside date. That caps the price at $26.61. Bain, which owns about 39% of the company, takes no cash and rolls its shares into the acquiring entity, and its agreement to vote for the deal stays in place.
Surgery Partners has not named the bidder. HERE Columbia6, which covered the deal, noted that UnitedHealth's Optum unit already owns a large network of surgery centers, a footprint that would draw antitrust review. Chief executive Eric Evans said in the announcement that "combining with HealthSpan Partners is the right next chapter for our company."
Third-quarter revenue was $815.3 million, down 0.8% from a year earlier, with adjusted EBITDA of $132.7 million and a net loss of $21.1 million attributable to the company. The company operated 173 surgical facilities at quarter end. It withdrew its guidance and canceled its earnings call because of the pending sale.
How the company got here
Bain Capital proposed in January 2025 to take Surgery Partners private at $25.75 a share, according to the company's statement5 at the time. That proposal never became a deal. On October 26, 2026, the company agreed4 to sell to HealthSpan at $23.50 a share, an enterprise value of about $5.7 billion, with Bain rolling its stake and the deal financed by cash and new debt. HealthSpan describes itself as a diversified health care services organization affiliated with Bon Secours Mercy Health, a Cincinnati-based system.
What comes next
Surgery Partners expects the sale to close in the first quarter of 2027, subject to a stockholder vote and regulatory approvals. The company told employees on Monday, in a filing3 of its internal questions and answers, that the proxy statement will be filed in the coming weeks. No meeting date has been set. The announcement says nothing about whether the third party could return with a revised offer, and UnitedHealth has not confirmed it made one.



